drugset / Trial / NCT01138098

Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children

NCT01138098

Phase 4 Completed 185 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the persistence of immunity to hepatitis B 10 to 11 years after vaccination with Infanrix hexa™ or Engerix™-B and also the ability to mount an immune response to the challenge dose of Engerix™-B.

Timeline

Start
2010-06-07
Primary completion
2010-11-26
Completion
2010-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine 10 ug Intramuscular